Sargramostim Clinical Trials
7 actively recruiting trials across 7 locations
▼ -2 trials since August 2026
Also known as: 23-L-Leucinecolony-Stimulating Factor 2, DRG-0012, GM-CSF, Granulocyte Macrophage Colony Stimulating Factor, Leukine +5 more
Pipeline
Top Sponsors
- University of Washington2
- University of Colorado, Denver1
- Northside Hospital, Inc.1
- Memorial Sloan Kettering Cancer Center1
- Mayo Clinic1
Indications
- Cancer6
- Metastatic Triple-Negative Breast Carcinoma2
- Anatomic Stage IV Breast Cancer AJCC v82
- Neuroblastoma2
- Stage IV Lung Cancer AJCC v82
Birmingham, Alabama1 trial
Children's Hospital of Alabama
Aurora, Colorado1 trial
University of Colorado Anschutz Medical Campus
Jacksonville, Florida1 trial
Mayo Clinic in Florida
Atlanta, Georgia1 trial
Northside Hospital
Omaha, Nebraska1 trial
University of Nebraska Medical Center
New York, New York1 trial
Memorial Sloan Kettering Cancer Center
Seattle, Washington1 trial
Fred Hutch/University of Washington Cancer Consortium
Trial data from ClinicalTrials.gov. Trial status and eligibility can change — verify directly with the study contact or on ClinicalTrials.gov.
This site does not provide medical advice. Always consult your doctor before considering enrollment in a clinical trial. Learn more on our About page.